Quince Therapeutics’ (QNCX) “Overweight” Rating Reiterated at Cantor Fitzgerald

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They presently have a $70.00 target price on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 105.16% from the company’s current price.

A number of other research firms have also commented on QNCX. Oppenheimer started coverage on Quince Therapeutics in a report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price target for the company. Zacks Research raised Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Lifesci Capital upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Monday, June 29th. Leerink Partners initiated coverage on Quince Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 target price for the company. Finally, Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $308.00.

Quince Therapeutics Trading Up 0.2%

Shares of QNCX stock opened at $34.12 on Tuesday. The firm’s 50 day moving average is $21.29 and its 200 day moving average is $29.32. The stock has a market capitalization of $34.80 million, a P/E ratio of -0.22 and a beta of 1.36. Quince Therapeutics has a 12 month low of $15.10 and a 12 month high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Friday, August 14th. The company reported ($12.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71. On average, equities analysts predict that Quince Therapeutics will post -2.72 EPS for the current year.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently modified their holdings of QNCX. BlackRock Inc. bought a new stake in Quince Therapeutics in the 2nd quarter worth approximately $31,000. XTX Topco Ltd purchased a new stake in Quince Therapeutics in the second quarter worth approximately $37,000. Intellectus Partners LLC bought a new position in Quince Therapeutics during the fourth quarter valued at approximately $179,000. Bridgeway Capital Management LLC grew its position in Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after acquiring an additional 22,200 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Quince Therapeutics during the fourth quarter worth approximately $213,000. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.